Vanguard Group Inc. Sells 118,686 Shares of Haemonetics Corporation $HAE

Vanguard Group Inc. trimmed its position in Haemonetics Corporation (NYSE:HAE) by 2.4% during the 3rd quarter, HoldingsChannel reports. The firm owned 4,834,646 shares of the medical instruments supplier’s stock after selling 118,686 shares during the period. Vanguard Group Inc. owned about 0.10% of Haemonetics worth $235,641,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently modified their holdings of HAE. EverSource Wealth Advisors LLC raised its position in Haemonetics by 2,640.0% during the second quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after acquiring an additional 396 shares in the last quarter. Versant Capital Management Inc raised its stake in shares of Haemonetics by 216.4% in the 3rd quarter. Versant Capital Management Inc now owns 829 shares of the medical instruments supplier’s stock valued at $40,000 after acquiring an additional 567 shares during the period. Byrne Asset Management LLC purchased a new stake in Haemonetics during the 3rd quarter worth approximately $42,000. Hantz Financial Services Inc. lifted its holdings in Haemonetics by 792.1% during the 3rd quarter. Hantz Financial Services Inc. now owns 1,124 shares of the medical instruments supplier’s stock worth $55,000 after buying an additional 998 shares during the last quarter. Finally, Elevation Point Wealth Partners LLC acquired a new stake in shares of Haemonetics in the second quarter valued at approximately $64,000. 99.67% of the stock is owned by hedge funds and other institutional investors.

Haemonetics Stock Performance

HAE opened at $63.28 on Monday. The stock’s 50 day simple moving average is $70.13 and its 200-day simple moving average is $64.19. The company has a current ratio of 1.75, a quick ratio of 1.15 and a debt-to-equity ratio of 1.01. The stock has a market cap of $2.94 billion, a PE ratio of 17.43, a P/E/G ratio of 1.32 and a beta of 0.28. Haemonetics Corporation has a 1 year low of $47.31 and a 1 year high of $87.32.

Haemonetics (NYSE:HAE) last released its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.04. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The firm had revenue of $338.97 million during the quarter, compared to analyst estimates of $331.90 million. During the same period in the prior year, the company posted $1.19 earnings per share. The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Sell-side analysts forecast that Haemonetics Corporation will post 4.55 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on HAE shares. CJS Securities raised shares of Haemonetics to a “strong-buy” rating in a research note on Thursday, December 11th. BTIG Research reaffirmed a “buy” rating and issued a $88.00 target price on shares of Haemonetics in a research report on Friday, February 6th. Barrington Research set a $94.00 price target on shares of Haemonetics in a research report on Friday, February 6th. Robert W. Baird set a $81.00 target price on Haemonetics in a research note on Friday, February 6th. Finally, Needham & Company LLC lowered shares of Haemonetics from a “buy” rating to a “hold” rating in a research report on Monday, December 15th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $84.44.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.